Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allogene Therapeutics, Inc.ALLO · Entity 5243 | Director | June 18, 2026 | June 23, 2026 |
| Science 37 Holdings, Inc.LSAQ · Entity 15235 | Director | November 20, 2020 | November 20, 2020 |
| UroGen Pharma Ltd.URGN · Entity 4466 | Chief Executive Officer | January 31, 2026 | February 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allogene Therapeutics, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 95,400 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 95,400 · Balance 95,400 F1: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i) 30 days following separation from continuous service with the company and (ii) a change in control of the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i) 30 days following separation from continuous service with the company and (ii) a change in control of the Company.
Science 37 Holdings, Inc.
Report date November 20, 2020 · Filed November 20, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,000 |
Reported balance
Holding disclosure · report date 2020-11-20 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 6,000 |
UroGen Pharma Ltd.
Report date January 31, 2026 · Filed February 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 153,195 |
Reported balance
After 2026-01-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-31 · Grant · Acquired 153,195 · Balance 153,195 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F2: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Sage Therapeutics, Inc.
Report date July 31, 2025 · Filed July 31, 2025
Section 16 reporting ended · disclosed 2025-07-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-07-31 transaction · row 1
1 source rowRow 1 · 2025-07-31 · Other · Disposed 3,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes. F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.77 · Expires 2034-06-10 | Direct | 0 |
Reported balance
After 2025-07-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-07-31 · Disposition to issuer · Disposed 21,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes.
F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025.
F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2020 Filed Jul 12, 2021 22:59 UTC Amendment | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 8,807 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-046344 · doc4a.xml · nonDerivative · entry 3 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: On December 4, 2020, the reporting person filed a Form 4 that inadvertently reported that a total of 61,652 shares vested on May 3, 2020. In fact, the shares vested monthly from June 3, 2020. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| July 03, 2020 Filed Jul 12, 2021 22:59 UTC Amendment | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 8,807 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-046344 · doc4a.xml · derivative · entry 9 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,534 Underlying: Ordinary Shares · 8,807 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F1 · date: On December 4, 2020, the reporting person filed a Form 4 that inadvertently reported that a total of 61,652 shares vested on May 3, 2020. In fact, the shares vested monthly from June 3, 2020. F3 · derivative.exercise_date: On January 3, 2019, the reporting person was granted restricted stock units ("RSUs") representing 317,065 ordinary shares. 1/3rd of the RSUs vested on January 3, 2020, with the balance vesting in equal monthly installments thereafter over a period of three years. F3 · derivative.expiration_date: On January 3, 2019, the reporting person was granted restricted stock units ("RSUs") representing 317,065 ordinary shares. 1/3rd of the RSUs vested on January 3, 2020, with the balance vesting in equal monthly installments thereafter over a period of three years. Read SEC document |
| July 03, 2020 Filed Jul 12, 2021 22:59 UTC Amendment | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 8,807 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-046344 · doc4a.xml · nonDerivative · entry 2 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: On December 4, 2020, the reporting person filed a Form 4 that inadvertently reported that a total of 61,652 shares vested on May 3, 2020. In fact, the shares vested monthly from June 3, 2020. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 03, 2020 Filed Jul 12, 2021 22:59 UTC Amendment | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 8,807 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-046344 · doc4a.xml · derivative · entry 8 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,341 Underlying: Ordinary Shares · 8,807 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F1 · date: On December 4, 2020, the reporting person filed a Form 4 that inadvertently reported that a total of 61,652 shares vested on May 3, 2020. In fact, the shares vested monthly from June 3, 2020. F3 · derivative.exercise_date: On January 3, 2019, the reporting person was granted restricted stock units ("RSUs") representing 317,065 ordinary shares. 1/3rd of the RSUs vested on January 3, 2020, with the balance vesting in equal monthly installments thereafter over a period of three years. F3 · derivative.expiration_date: On January 3, 2019, the reporting person was granted restricted stock units ("RSUs") representing 317,065 ordinary shares. 1/3rd of the RSUs vested on January 3, 2020, with the balance vesting in equal monthly installments thereafter over a period of three years. Read SEC document |
| June 03, 2020 Filed Jul 12, 2021 22:59 UTC Amendment | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 8,807 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-046344 · doc4a.xml · nonDerivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: On December 4, 2020, the reporting person filed a Form 4 that inadvertently reported that a total of 61,652 shares vested on May 3, 2020. In fact, the shares vested monthly from June 3, 2020. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 12, 2020 Filed May 14, 2020 17:07 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 35,229 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-029079 · doc4.xml · derivative · entry 2 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,148 Underlying: Ordinary Shares · 35,229 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 3, 2019 representing 317,065 ordinary shares. 33.33% of the RSUs vested on January 3, 2020. The remaining unvested restricted stock units will vest at a rate of 2.778% in equal monthly installments thereafter. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 3, 2019 representing 317,065 ordinary shares. 33.33% of the RSUs vested on January 3, 2020. The remaining unvested restricted stock units will vest at a rate of 2.778% in equal monthly installments thereafter. Read SEC document |
| May 12, 2020 Filed May 14, 2020 17:07 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 35,229 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-029079 · doc4.xml · nonDerivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the settlement of restricted stock units that vested from February 3, 2020 through May 3, 2020 through the issuance of ordinary shares. Read SEC document |
| May 03, 2020 Filed Jul 12, 2021 22:57 UTC Amendment | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 8,808 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-046340 · doc4a.xml · derivative · entry 8 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,148 Underlying: Ordinary Shares · 8,808 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F1 · date: On May 14, 2020, the reporting person filed a Form 4 that inadvertently reported that a total of 35,229 shares vested on May 3, 2020. In fact, the shares vested monthly from February 3, 2020. F3 · derivative.exercise_date: On January 3, 2019, the reporting person was granted restricted stock units ("RSUs") representing 317,065 ordinary shares. 1/3rd of the RSUs vested on January 3, 2020, with the balance vesting in equal monthly installments thereafter over a period of three years. F3 · derivative.expiration_date: On January 3, 2019, the reporting person was granted restricted stock units ("RSUs") representing 317,065 ordinary shares. 1/3rd of the RSUs vested on January 3, 2020, with the balance vesting in equal monthly installments thereafter over a period of three years. Read SEC document |
| May 03, 2020 Filed Jul 12, 2021 22:57 UTC Amendment | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 8,808 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-046340 · doc4a.xml · nonDerivative · entry 4 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: On May 14, 2020, the reporting person filed a Form 4 that inadvertently reported that a total of 35,229 shares vested on May 3, 2020. In fact, the shares vested monthly from February 3, 2020. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| April 03, 2020 Filed Jul 12, 2021 22:57 UTC Amendment | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 8,807 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-046340 · doc4a.xml · derivative · entry 7 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,956 Underlying: Ordinary Shares · 8,807 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F1 · date: On May 14, 2020, the reporting person filed a Form 4 that inadvertently reported that a total of 35,229 shares vested on May 3, 2020. In fact, the shares vested monthly from February 3, 2020. F3 · derivative.exercise_date: On January 3, 2019, the reporting person was granted restricted stock units ("RSUs") representing 317,065 ordinary shares. 1/3rd of the RSUs vested on January 3, 2020, with the balance vesting in equal monthly installments thereafter over a period of three years. F3 · derivative.expiration_date: On January 3, 2019, the reporting person was granted restricted stock units ("RSUs") representing 317,065 ordinary shares. 1/3rd of the RSUs vested on January 3, 2020, with the balance vesting in equal monthly installments thereafter over a period of three years. Read SEC document |
| April 03, 2020 Filed Jul 12, 2021 22:57 UTC Amendment | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 8,807 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-046340 · doc4a.xml · nonDerivative · entry 3 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,657 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: On May 14, 2020, the reporting person filed a Form 4 that inadvertently reported that a total of 35,229 shares vested on May 3, 2020. In fact, the shares vested monthly from February 3, 2020. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 03, 2020 Filed Jul 12, 2021 22:57 UTC Amendment | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 8,807 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-046340 · doc4a.xml · derivative · entry 6 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,763 Underlying: Ordinary Shares · 8,807 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F1 · date: On May 14, 2020, the reporting person filed a Form 4 that inadvertently reported that a total of 35,229 shares vested on May 3, 2020. In fact, the shares vested monthly from February 3, 2020. F3 · derivative.exercise_date: On January 3, 2019, the reporting person was granted restricted stock units ("RSUs") representing 317,065 ordinary shares. 1/3rd of the RSUs vested on January 3, 2020, with the balance vesting in equal monthly installments thereafter over a period of three years. F3 · derivative.expiration_date: On January 3, 2019, the reporting person was granted restricted stock units ("RSUs") representing 317,065 ordinary shares. 1/3rd of the RSUs vested on January 3, 2020, with the balance vesting in equal monthly installments thereafter over a period of three years. Read SEC document |
| March 03, 2020 Filed Jul 12, 2021 22:57 UTC Amendment | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 8,807 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-046340 · doc4a.xml · nonDerivative · entry 2 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: On May 14, 2020, the reporting person filed a Form 4 that inadvertently reported that a total of 35,229 shares vested on May 3, 2020. In fact, the shares vested monthly from February 3, 2020. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 03, 2020 Filed Jul 12, 2021 22:57 UTC Amendment | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 8,807 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-046340 · doc4a.xml · derivative · entry 5 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,570 Underlying: Ordinary Shares · 8,807 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F1 · date: On May 14, 2020, the reporting person filed a Form 4 that inadvertently reported that a total of 35,229 shares vested on May 3, 2020. In fact, the shares vested monthly from February 3, 2020. F3 · derivative.exercise_date: On January 3, 2019, the reporting person was granted restricted stock units ("RSUs") representing 317,065 ordinary shares. 1/3rd of the RSUs vested on January 3, 2020, with the balance vesting in equal monthly installments thereafter over a period of three years. F3 · derivative.expiration_date: On January 3, 2019, the reporting person was granted restricted stock units ("RSUs") representing 317,065 ordinary shares. 1/3rd of the RSUs vested on January 3, 2020, with the balance vesting in equal monthly installments thereafter over a period of three years. Read SEC document |
| February 03, 2020 Filed Jul 12, 2021 22:57 UTC Amendment | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 8,807 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-046340 · doc4a.xml · nonDerivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: On May 14, 2020, the reporting person filed a Form 4 that inadvertently reported that a total of 35,229 shares vested on May 3, 2020. In fact, the shares vested monthly from February 3, 2020. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 17:36 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Unit · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-006208 · doc4.xml · derivative · entry 2 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: 1/3rd of the shares underlying the RSU vest on January 31, 2021 and 1/12th of the shares underlying the RSU vest in 8 quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date. F3 · derivative.expiration_date: 1/3rd of the shares underlying the RSU vest on January 31, 2021 and 1/12th of the shares underlying the RSU vest in 8 quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 17:36 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantStock options (right to buy) · Derivative | 45,000 | $0.00 Strike: $29.41 | $0.00 |
DisclosureSEC source: 0001209191-20-006208 · doc4.xml · derivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Ordinary Shares · 45,000 shares Expires not disclosed F1 · derivative.exercise_date: 1/3rd of the shares underlying the stock option vest on January 31, 2021 and 1/12th of the shares underlying the stock option vest in 8 quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date. F1 · derivative.expiration_date: 1/3rd of the shares underlying the stock option vest on January 31, 2021 and 1/12th of the shares underlying the stock option vest in 8 quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 23:30 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares · Derivative | 105,688 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002366 · doc4.xml · derivative · entry 2 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,377 Underlying: Ordinary Shares · 105,688 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: On January 3, 2018, the reporting person was granted 317,065 restricted stock units of which 33% vested on January 3, 2020. The remaining unvested restricted stock units will vest at a rate of 2.778% in equal monthly installments thereafter. F3 · derivative.expiration_date: On January 3, 2018, the reporting person was granted 317,065 restricted stock units of which 33% vested on January 3, 2020. The remaining unvested restricted stock units will vest at a rate of 2.778% in equal monthly installments thereafter. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 23:30 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 105,688 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002366 · doc4.xml · nonDerivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the settlement of restricted stock units that vested on January 3, 2020 through the issuance of ordinary shares. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 20:34 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | PurchaseOrdinary Shares | 7,530 | $28.00 | $210,840.00 |
DisclosureSEC source: 0001209191-19-057766 · doc4.xml · nonDerivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,548 Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 18:35 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | PurchaseOrdinary Shares | 7,470 | $28.00 | $209,160.00 |
DisclosureSEC source: 0001209191-19-057755 · doc4.xml · nonDerivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,018 Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 00:32 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | PurchaseOrdinary Shares | 1,548 | $26.00 | $40,248.00 |
DisclosureSEC source: 0001209191-19-057044 · doc4.xml · nonDerivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,548 Read SEC document |
| January 03, 2018 Filed Jan 10, 2019 01:25 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Unit · Derivative | 317,065 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-003174 · doc4.xml · derivative · entry 2 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,065 Underlying: Ordinary Shares · 317,065 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 33% of the RSUs will vest on January 3, 2020 and the remaining RSUs will vest 2.778% in equal monthly installments thereafter. F3 · derivative.expiration_date: 33% of the RSUs will vest on January 3, 2020 and the remaining RSUs will vest 2.778% in equal monthly installments thereafter. Read SEC document |
| January 03, 2018 Filed Jan 10, 2019 01:25 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantEmployee Stock Option (right to buy) · Derivative | 277,432 | $0.00 Strike: $47.57 | $0.00 |
DisclosureSEC source: 0001209191-19-003174 · doc4.xml · derivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,432 Underlying: Ordinary Shares · 277,432 shares Expires 2029-01-03 F1 · derivative.exercise_date: 33% of the shares underlying the stock option will vest on January 3, 2020 and 2.778% of the remaining shares will vest in equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.